From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

The BladderPath trial indicates that mpMRI can expedite MIBC treatment and improve bladder cancer-specific survival compared to traditional TURBT. The study showed a significant improvement in BCSS ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

Treatment recommendations for all stages of bladder cancer have been proposed in the form of clinical guidelines from the European Association of Urology and the American Urological Association.

The trial, also referred to as KEYNOTE-905, met its primary end point of EFS, resulting in a 60% reduction in the risk of tumor recurrence, progression, or death of patients treated with neoadjuvant ...

A study published in Nature by researchers at IRB Barcelona and the University of Washington shows that smoking and biological sex influence how mutated cells expand in healthy bladder tissue. The ...

The "Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2025" report highlights significant R&D opportunities with over 20 companies and 22 pipeline drugs, focusing on innovative treatments like ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, ...